Can Oral Wegovy Help Novo Nordisk Capture China’s $4.46 Billion GLP-1 Opportunity?

Novo Nordisk has submitted an application for marketing approval of its oral Wegovy treatment in China, positioning the company to tap into a potentially lucrative $4.46 billion GLP-1 therapy market. The country's National Health Commission estimates that over 65% of its population may be overweight or obese by 2030, presenting a substantial opportunity for weight-management treatments.

J.P. Morgan estimates Chinese sales of GLP-1 therapies could reach 30 billion yuan ($4.46 billion) in the next five to seven years. An oral formulation of Wegovy could provide Novo Nordisk with an alternative to injectable medicines, appealing to patients who avoid treatment due to needle-phobia. Novo Nordisk's approval in the U.S. and Britain, and its successful launch in the U.S., suggest the product has already passed regulatory assessment in two major markets, though this does not guarantee success in China.

The Chinese regulator has accepted the application but has not provided a timeline for approval, making it difficult to predict when the treatment could become commercially available. Novo Nordisk faces competition from Eli Lilly, Pfizer, and China-based Innovent Biologics in the injectable GLP-1 weight-management products market, and the 30-billion-yuan market projection is an analyst estimate rather than a definitive sales projection.